 ANN ARBOR, Mich., April 26, 2021 GLOBE NEWSWIRE -- Esperion Therapeutics NASDAQ: ESPR today announced that an investor group led by Oberland Capital Management LLC Oberland Capital agreed to provide the third and final tranche of funding under the revenue-based funding agreement totaling 50 million. The remaining funds are being released sooner than expected and in parallel with Esperion announcing an expansion of an ex-U.S. commercial agreement with an existing partner for select strategic geographies outside of the United States, Europe and Japan. 